The inhibition of BRD4, a member of the Bromodomain and ExtraTerminal (BET) family of bromodomain-containing proteins, was recently shown to reduce levels of Androgen Receptor (AR) driven target genes in prostate cancer, and reduce tumor burden in murine models [12]. This evidence concerns the gene BRD4 and neoplasm.